Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-11-28
2006-11-28
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S190100, C424S184100, C424S185100, C530S350000, C530S300000, C530S825000, C514S002600, C435S071100, C435S069300
Reexamination Certificate
active
07141244
ABSTRACT:
This invention provides polypeptides ofHelicobacter pyloricytotoxin associated immunodominant (CAI) antigen. The invention also provides prophylactic and therapeutic vaccines comprising polypeptides ofHelicobacter pyloriCAI antigen, and methods for their preparation. The invention also provides methods of treatment ofHelicobactor pyloriinfection using these vaccines.
REFERENCES:
patent: 4882271 (1989-11-01), Evans et al.
patent: 5403924 (1995-04-01), Cover et al.
patent: 5541291 (1996-07-01), Keene
patent: 5721349 (1998-02-01), Cover et al.
patent: 5866375 (1999-02-01), Figura et al.
patent: 5900372 (1999-05-01), Figura et al.
patent: 6054132 (2000-04-01), Cover et al.
patent: 0329570 (1989-08-01), None
patent: 0367644 (1990-05-01), None
patent: WO 87/05943 (1987-10-01), None
patent: WO 89/08843 (1989-09-01), None
patent: WO 90/04030 (1991-04-01), None
patent: WO 91/09049 (1991-06-01), None
Cover et al. Infection and Immunity, Mar. 1990, vol. 58, No. 3, p. 603-610.
Peterson et al. Nature 354: 369-373, 1991 (abstract).
Hirschl et al. Eur. J. Clin. Microbiol. Infect. Dis. 7: 570-575, 1988.
Petersen et al. Nature 354: 369-373, 1991.
Hirschl et al. In:Helicobacter pylori, gastritis and peptic ulcer. (Ed) Malfertheiner et al. Springer-Verlag, Berlin Heidelberg, 141-146, 1990.
Harlow et al. In: Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Chapter 5, p. 76, 1988.
Austin et al., “Structural Comparison of Urease and a GroEl Analog fromHelicobacter pylori”, J. Bacteriol., 1992, 174(22), 7470-7473.
Apel et al., “Antibody Response of Patients Against a 120 kDa Surface Protein ofCampylobacter pylori”, Aentralblat fur Bakterio. Microb. Und Hygiene, 1988, 268, 271-276.
Blaser, “GastricCampylobacter-like Organisms, Gastritis, and Peptic Ulcer Disease”,Gastroenterology, 1987, 93, 371-383.
Blaser, “Helicobacter pylori: Its Role in Disease”,Clin. Infect. Dis., 1992, 15, 386-391.
Blaser, M., “H.pyloriassociated disease involves host and bacterial factors,”HP World-Wide, Feb. 1992, 1-8.
Clayton, C.L. et al., “Molecular Cloning Expression ofCampylobacter pyloriSpecies-Specific Antigens inEscherichia coliK-12,”Infection Immunity, 1989, 57(2), 623-629.
Cover et al., “Purification and Characterization of the Vacuolating Toxin fromHelicobacter pylori”, J. Biol. Chem.,1992, 267(15), 10570-10575.
Cover et al., “Serum Neutralizing Antibody Response to the Vacuolating Cytotoxin ofHelicobacter pylori”, J. Clin. Invest.,1992, 90, 913-918.
Cover et al., “Human serologic response toCampylobacter pyloricytotoxin-associated proteins”,Gastroenterology, 1989, 96 (5/2), A101, abstract.
Crabtree et al., “Expression of 120 kilodalton protein and cytotoxicity inHelicobacter pylori”, J. Clin. Pathol.,1992, 45, 733-734.
Cussac et al., “Expression ofHelicobacter pyloriUrease Genes inEscherichia coliGrown under Nitrogen-Limiting Conditions”,J. Bacteroil.,1992, 174(8), 2466-2473.
Dooley et al., “Prevalence ofHelicobacter pyloriInfection and Histologic Gastritis in Asymptomatic Persons”,New Engl. J. Med.,1989, 321, 1562-1566.
Drumm et al., “Intrafamilial Clustering ofHelicobacter pyloriInfection”,New Engl. J. Med.,1990, 322(6), 359-363.
Dunn et al., “Identification and Purification of a cpn60 Heat Shock Protein Homolog fromHelicobacter pylori”, Infect. Immun.,1992, 60(5), 1946-1951.
Evans et al., “Urease-Associated Heat Shock Protein ofHelicobacter pylori”, Infect. Immun.,1992, 60(5), 2125-2127.
Evans et al., “A Sensitive and Specific Serologic Test for Detection ofCampylobacter pyloriInfection”,Gastroenterology, 1989, 96, 1004-1008.
Gerstenecker et al., “Serodiagnosis ofHelicobacter pyloriInfections with an Enzyme Immunoassay Using the Chromatographically Purified 120 Kilodalton Protein”,Eur. J. Clin. Microbiol. Infect. Dis.,1992, 11(7), 595-601.
Goodwin et al., “Transfer ofCampylobacter pyloriandCampylobacter mustelaetoHelicobactergen. nov. AsHelicobacter pyloricomb. Nov. AndHelicobacter mustelaecomb. Nov., Respectively,”Int. J. Syst. Bacteriol.,1989, 39(4), 397-405.
Graham et al., “Epidemiology ofHelicobacter pyloriin an Asymptomatic Population in the United States”,Gastroenterology, 1991, 100, 1495-1501.
Graham et al., “Seroepidemiology ofHelicobacter pyloriInfection in India: Comparison of Developing and Developed Countries”,Digestive Diseases and Sciences, 1991, 36(8), 1084-1088.
Jones et al., “Antibody to the gastricCampylobacter-like organism (“Campylobacter pyloridis”)—Clinical correlations and distribution in the normal population”,Med. Microbiol.,1986, 22, 57-62.
Kahn, S. et al., “The major 85-KD surface antigen of the mammalian form ofTrypanosoma cruziis encoded by a large heterogeneous family of simultaneously expressed genes,”J. Exp. Med.,1990, 172(2), 589-597.
Leunk, “Production of a Cytotoxin byHelicobacter pylori”, Rev. Infect. Dis.,1991, 13(8), S686-S689.
Leying et al., “Cloning and genetic characterization of aHelicobacter pyloriflagellin gene”,Mol. Microbiol.,1992, 6(19), 2863-2874.
Morris et al., “Seroepidemiology ofCampylobacter pyloridis”, N.Z. Med. J.,1986, 99(809), 657-659.
Orkin, S.H. et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 1995, 41 pages.
Parsonnet et al., “Helicobacter pyloriInfection and the Risk of Gastric Carcinoma”,New Engl. J. Med.,1991, 325(16), 1127-1131.
Pei, Z. et al., “Identification Purification and Characterization of Major Antigenic Proteins of Campylobacter-Jejuni,”J. Biol. Chem.,1991, 266(25), 16363-16369.
Perez-Perez et al., “Characteristics ofHelicobacter pyloriVariants Selected for Urease Deficiency”,J. Infect. Immun.,1992, 60(9), 3658-3663.
Thomas et al., “Isolation ofHelicobacter pylorifrom human faeces”,Lancet, 1992, 340, 1194-1195.
Warren et al., “Unidentified Curved Bacilli on Gastric Epithelium in Active Chronic Gastritis”,Lancet, 1983, 1273-1275.
Figura, N et al., “Serum antibodies to the vacuolating toxin produced byHelicobacter pylori”, Helicobacter pylori, Gastritis and Peptic Ulcer, Malfertheiner et al. (Eds), Springer Verlag, Berlin, 1990, pp. 169-161.
Gerken, et al., sequence submitted to EST-STS by Utah Center for Human Genome Res. University of Utah, 1993, Accession No. L18544.
Covacci, A. et al., “Molecular characterization of the 128-kDa immunodominant antigen ofHelicobacter pyloriassociated with cytotoxicity and duodenal ulcer”,Proc. Natl. Acad. Sci. USA, 1993, 90(12), 5791-5795.
Tummuru, M.K.R., “Cloning and Expression of a High-Molecular-Mass Mjor Antigen ofHelicobacter pylori: Evidence of Linkage to Cytotoxin Production”,Infection and Immunity, 1993, 61(5),1799-1809.
Bugnoli Massimo
Covacci Antonello
Macchia Giovanni
Rappuoli Rino
Telford John
Chiron SRL
Devi S.
Woodcock & Washburn LLP
LandOfFree
Helicobacter pylori proteins useful for vaccines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Helicobacter pylori proteins useful for vaccines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Helicobacter pylori proteins useful for vaccines and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3663534